JAGXJaguar Animal Health
About Jaguar Animal Health
Jaguar Animal Health (NASDAQ:JAGX) is a company focused on developing and commercializing gastrointestinal products for both domestic and wild animals. Pioneering innovative solutions, Jaguar aims to improve animal health management and outcomes across a broad spectrum of species. The company's projects range from prescription and non-prescription medications to biome-based therapies, geared towards addressing significant market needs in the veterinary health sector. Jaguar's primary objective is to enhance the quality of veterinary care through its diverse product portfolio, ensuring animals lead healthier and more comfortable lives. Presently, Jaguar Animal Health trades on the NASDAQ under the ticker symbol JAGX, showcasing its commitment to advancing animal health on a global scale.
What is JAGX known for?
Snapshot
Public US
Ownership
2013
Year founded
60
Employees
San Francisco, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
San Francisco, US
Products and/or services of Jaguar Animal Health
- Gastrointestinal products for domestic and production animals to improve digestive health and nutrient absorption.
- Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, enhancing their comfort and treatment effectiveness.
- Equilevia, a personalized, premium gut health product for horses, designed to support overall wellness and performance.
- Neonorm Calf, a botanical extract for newborn calves to reduce water loss from scours and improve hydration.
- Herbal extract formulations for animal gastrointestinal health, leveraging traditional knowledge with modern science.
- Collaborative research on novel animal health solutions, focusing on natural and sustainable remedies.
Jaguar Animal Health executive team
- Ms. Lisa A. ConteFounder, CEO, President & Director
- Dr. Pravin R. Chaturvedi Ph.D.Chief Scientific Officer & Chair of Scientific Advisory Board
- Mr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & General Counsel
- Dr. Steven R. King Ph.D.Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
- Ms. Carol R. Lizak M.B.A.Chief Financial Officer
- Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special Events
- Dr. Karen J. Brunke Ph.D.Executive VP of Corporate & Business Development
- Mr. David Sesin Ph.D.Chief Manufacturing Officer
- Mr. Ian H. Wendt M.B.A.Chief Commercial Officer
- Dr. Massimo Radaelli M.B.A., Ph.D.President of Jaguar International